Responses
Clinical and epidemiological research
Extended report
Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 13 April 2016
- Published on: 13 April 2016Running away from your own dataShow More
Dear Editor,
This is an interesting paper; however I was surprised at the vagueness of the conclusion. The authors showed a significantly increased 'ratio of lymphoma' with adalimumab (4.1) and infliximab (3.6) vs. entanercept (0.9). Unless some confounding variable is discovered, the conclusion would seem clear. Either adalimumab and infliximab predispose to lymphoma, or entanercept prevents it.
The 'conclusion'...
Conflict of Interest:
None declared.